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Background: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of
isoflavone, may be attributed to a person’s ability to produce equol from daidzein. Equol, which is a metabolite of
one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal
microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the
metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as
well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation
increases equol production in equol producers and stimulates equol production in equol non-producers in
Japanese postmenopausal women.
Methods: A soy challenge was used to assess equol-producer status prior to the start of the study in healthy
postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First,
subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly
assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the
capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study
design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation
period.
Results: The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol
producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time ×
equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention
(p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum
equol concentration or the urinary equol to daidzein concentration ratios.
Conclusions: We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the
capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or
non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in
equol production will enable the establishment of dietary conditions that are required to enhance equol production.
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Soybean isoflavones are structurally similar to oestrogen;
they exhibit a weak affinity for oestrogen receptors, ERα
and ERβ, eliciting mild oestrogenic-like activity in vari-
ous tissues [1]. On the other hand, the isoflavones genis-
tein and daidzein have been shown previously to possess
anti-oestrogenic activity in human breast cancer cells
in vitro [2]. Compared with ERα, ERβ exhibits a greater
binding affinity for isoflavone, whereas oestrogen binds
to ER with equal affinity [3]. The relatively selective
binding of isoflavones to ERβ indicates that isoflavones may
confer distinct clinical effects compared with oestrogen [4].
Moreover Hwang et al. reported that isoflavones may exert
their effects as oestrogen antagonists in a high oestrogen
environment, or they may act as oestrogen agonists in a
low oestrogen environment [5].
Isoflavones have received considerable attention be-
cause of their potential to prevent postmenopausal con-
ditions such as cardiovascular disease [6], osteoporosis
[7], and hormone-dependent cancers [8]. Daidzein, a
major soybean isoflavone, is metabolized to equol in the
gastrointestinal tract by intestinal microbiota. Recent
studies suggest that some of the clinical effectiveness of
soy or daidzein, which is a type of isoflavone, can be at-
tributed to a person’s ability to produce equol from daid-
zein via their intestinal bacteria, because its biological
activities differ from those of its precursor [9]. However,
not all healthy humans produce equol. The ability to
produce equol depends on the presence of certain intes-
tinal microbiota. Many studies have provided that only
25-30% of the adult population of Western countries
produce equol when fed soy foods containing isoflavones
[10-12]. This is significantly lower than the reported 50-
60% of equol producers in adults from Asian countries
[13-15]. The reasons for these differences are unclear,
but dietary changes can alter the microbiotal profile of
the intestine. Therefore, habitual dietary patterns may
influence the metabolism of isoflavone and the produc-
tion of equol [16]. Several studies comparing the habit-
ual diets of equol producers and non-producers who
consume Western diets have reported that equol pro-
ducers tend to have a higher intake of carbohydrate and
dietary fibre, a higher percentage of energy as carbohy-
drate and lower percentage of energy as fat, and intake
of soy, plant protein [10,12,17]; however, this has not
been a consistent observation.
On the other hand, soy products are traditionally used
in many Asian countries. The intake of traditional soy-
based foods is high in Japan, and the mean total intake
of isoflavones is estimated between 19.4 and 33.6 mg/d
according to the National Nutritional Survey in Japan
[18]. In Western populations, the consumption of isoflavones
from traditional soy foods is substantially lower (between
0.5 and 3 mg) than that of Japan [19-21]. In Westerncountries, a portion of total isoflavone consumption is
derived from soy protein and soy flour added to a variety
of foods.
While it is not clearly understood how bacterial spe-
cies produce equol in the intestine, certain Lactobacillus
and Bifidobacteria species have been suggested to play a
role in the metabolism of daidzein to equol [22,23].
Fructooligosaccharides (FOS) have prebiotic activity in
addition to being a form of dietary fibre [24,25]. FOS are
poorly digested in the human small intestine and are
fermented in the colon by Lactobacillus and Bifidobacteria
species; moreover, FOS stimulates their growth.
To date, a few studies have reported the effects of diet-
ary fibre and/or prebiotics on isoflavone bioavailability
in Western population [26-28], but no intervention stud-
ies have examined the effect of FOS on equol production
in Japanese. The purpose of the present study was to de-
termine whether FOS supplementation increases equol
production in equol producers and stimulates equol pro-




The protocol was approved by the Institutional Review
Board of the National Institute of Health and Nutrition
of Japan, and the study was performed in accordance
with the guidelines of the Declaration of Helsinki. All
women provided their written informed consent to par-
ticipate in the study.
Subjects and design
In this study, 43 healthy postmenopausal women who
fulfilled the required criteria were recruited and screened.
The exclusion criteria for this study were history of
chronic renal or hepatic disease, history of hormone
replacement therapy or breast cancer, serum oestrogen
hormone (E2) concentration > 50 pg/mL, soy allergies,
and any other medication known to affect bone. A soy
challenge was used to assess equol-producer status
prior to the start of this study. The day before sample
collection, subjects ingested soy food containing 22
mg soy isoflavones. On sample collection day, morn-
ing urine samples were collected from the subjects,
and they were stratified into equol producers or non-
producers based on their urinary equol to daidzein con-
centration ratio [Equol producer: Log (urinary equol/
daidzein) > −1.70].
The study comprises 4 separate groups in a random-
ized crossover design (Figure 1). Subjects were identified
by a single randomisation number using a computer-
generated random permutation procedure in SPSS soft-
ware version 11.0J. The study design involved two 2-week
dietary periods separated by a 2-week washout. During
Figure 1 Study design. Subjects were classified as equol producers or non-producers and were further assigned to 2 groups as follows: ISO + control,
intervention with soy isoflavone supplement and sucrose; ISO + FOS, intervention with soy isoflavone supplement and fructooligosaccharides. ISO,
isoflavones; FOS, fructooligosaccharides.
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additional soy isoflavone supplements that could poten-
tially affect intestinal bacteria were excluded from the
diet. Subjects were instructed to otherwise maintain
their normal diets for the duration of the study. The
washout period required the same dietary exclusions
as the intervention periods. Studies have shown that
antibiotic-associated changes in faecal flora are nor-
mally reversed in 10–14 days after the stopping of
treatment [29,30]. Therefore, a 2-week washout period
was set in our study, although antibiotics were not
used by any of the participants during the study. The
subject randomisation codes were allocated sequentially in
the order in which the subjects were enrolled. After com-
pletion of all the analyses, the randomisation code was
disclosed to the investigators and subjects.
All subjects received a daily dose of 37 mg isoflavone
conjugates in the capsule (Fujiflavone P40; Fujicco Co.,
Ltd., Kobe, Japan; 21 mg aglycone form) and 5 g of
either FOS (Meioligo; Meiji Seika Kaisha Ltd., Tokyo,
Japan) or sucrose (white sugar; Mitsui Sugar Co., Ltd.,
Tokyo, Japan) as control. Each subject consumed the
isoflavone capsule and FOS or sucrose at breakfast.
Digestive products may stimulate the growth of certain
microbiota, and FOS may selectively stimulate the growth
of certain microbiota. As sucrose is digested readily, we
used that as the control in this study. Dietary assessments
of dietary soy isoflavones and nutrient intake based on
3-day dietary records were obtained at baseline. Fasting
blood samples were collected at baseline and after 2 weeks
of intervention. Spot urinary samples were collected at
baseline and after 1 and 2 weeks of intervention.
Isoflavones supplement
The crude isoflavone conjugate (40% isoflavones) in the
capsule were daidzin (20.4%), malonyldaidzin (0.1%),acetyldaidzin (1.1%), daidzein (0.3%), genistin (4.6%),
acetylgenistin (0.3%), genistein (0.1%), and glycitin plus
glycitein (13%). As aglycones, 33 mg daidzein, 8.5 mg
genistein, and 15 mg glycitein were included in the 100
mg of conjugates. Thus, 37 mg of conjugated isoflavones
equivalent to 21.1 mg aglycone, which consisted of 12.3
mg daidzein, 3.2 mg genistein, and 5.6 mg glycitein,
existed in each capsule.
Measurement of serum and urinary daidzein and equol
concentrations
The concentrations of daidzein and equol in blood and urine
were analysed by the time-resolved fluoroimmunoassay
method; the detection limits of daidzein and equol in
these assays were 2.0 nM and 3.3 nM, respectively [31,32].
Statistical analysis
All values are expressed as mean ± SD, and P < 0.05 was
considered significant. The differences in isoflavone and
nutritional intake between equol producers and non-
producers were examined by using unpaired Student’s t-
test. The differences in the serum equol concentrations
at baseline and after 2 weeks of intervention were exam-
ined by using paired Student’s t-test. Three-way ANOVA
(factors of FOS intervention, time, and equol status) was
performed to determine the effect of dietary interven-
tion on the urinary equol to daidzein concentration
ratios. The changes in the urinary equol to daidzein con-
centration ratios in each group were evaluated by repeated-
measures ANOVA and the Tukey post hoc test. All
analyses were performed by using SPSS (SPSS 11.0;
SPSS Inc., Chicago, IL, USA).
Results and discussion
At the beginning of the study, 43 subjects (25 equol pro-
ducers, 18 non-producers) were recruited. Nine subjects
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because they had taken oral antibiotics (4 subjects). The
remaining 34 subjects completed the study, 21 (61.8%)
were classified as equol producers, and 13 (38.2%) as
non-producers. Characteristics of the subjects and their
daily intake of isoflavones and nutrients at baseline are
shown in Table 1. There were no major differences in
age, height, weight, and body mass index between the
equol producers and non-producers. The average daily
intake of isoflavones from soy foods (other than isofla-
vone supplements) in each group ranged from 41.6–54.8
mg. Except for the fat intake, there were no significant
differences between the daily intake of isoflavones and
nutrients in the equol producers or non-producers. The
average daily fat intake in equol producers (56.3 ±
13.7 g) was significantly higher compared to non-producers
(49.1 ± 13.6 g). Epidemiological studies have been
performed investigating the effects of habitual diet on
equol production. Aldercreutz et al. found that the intake
of total fat and meat and the dietary ratio of fat to fibre
correlated with the urinary excretion of equol in a Japanese
population [33], our result is consistent with this previous
study. Whereas in a Western population, Rowland et al.
reported that equol producers consumed significantly less
energy as fat and significantly more energy as carbohydrate
than equol non-producers [12]. The effects of habitual diet
on equol production are controversial.
The serum equol concentrations in the equol pro-
ducers and non-producers were 38.0 ± 24.8 nmol/L andTable 1 Equol producers and non-producers: subject





n = 21 n = 13
Age (year) 53.1 ± 4.3 54.4 ± 3.8 0.168
Height (cm) 155.6 ± 4.7 155.2 ± 4.6 0.776
Weight (kg) 52.5 ± 7.4 51.5 ± 4.6 0.504
Body mass index
(kg/m2)
21.6 ± 1.7 21.1 ± 2.3 0.328
Daily intake
Isoflavones (mg) 41.6 ± 22.0 54.8 ± 48.7 0.195
Energy (kcal) 1820 ± 284 1796 ± 352 0.765
Protein (g) 72.0 ± 14.7 71.9 ± 14.5 0.986
Fat (g) 56.3 ± 13.7 49.1 ± 13.6 0.038
Carbohydrate (g) 246 ± 51 261 ± 54 0.264
Calcium (mg) 630 ± 167 639 ± 232 0.855
Dietary fibre (g) 17.3 ± 4.4 19.6 ± 8.4 0.212
1All values are mean ± SD.
2Differences in age, height, weight, body mass index, and daily isoflavone and
nutrient intake between equol producers and non-producers were examined
by using unpaired t-tests.23.2 ± 19.0 nmol/L, respectively, and that of the equol
producers was significantly higher than that of the non-
producers (p = 0.008). Among the equol producers,
serum equol concentrations in both the FOS and control
groups significantly increased after 2-week of interven-
tion (Figure 2). However, there were no significant differ-
ences in serum equol levels between the FOS and
control groups in the equol producers. The similarly
increased serum equol concentrations in the FOS and
control groups among equol producers may have been
stimulated by the isoflavone supplement. Among the
equol non-producers, there were no significant differences
in serum equol concentrations between the FOS and con-
trol groups at baseline and after 2 weeks of intervention.
Thus, FOS intervention did not affect serum equol pro-
duction as compared to sucrose intervention as control in
the equol producers or non-producers who were treated
with isoflavones in this study.
Setchell et al. have reported that expressing the product-
precursor relationship as the urinary equol to daidzein
concentrations ratio is a more reliable indicator of the con-
version of daidzein to equol [34]. Among the equol pro-
ducers and non-producers, 1- or 2-week FOS intervention
had no effect on the capacity of colonic microbiota to pro-
duce equol (Table 2). Among the equol producers, urinary
equol to daidzein concentration ratios in both the FOS andFigure 2 Serum equol concentrations of different study groups
at baseline and after 2 weeks of intervention. EQ (+), equol
producers; EQ (−), equol non-producers. Data is expressed as mean ±
SD. Data was analyzed using a paired t-test. * Statistically significant
(P < 0.05). The differences in the serum equol concentrations at
baseline and after 2 weeks of intervention were examined using a
paired Student’s t-test.
Table 2 Changes in urinary equol to daidzein concentration ratios in postmenopausal women1
Equol producer Equol non-producer P-value
(n = 21) (n = 13) 3-way ANOVA3
Main effects Interactions
FOS2 Control FOS Control FOS Time Equol state FOS × time FOS × equol state Time × equol state FOS × time × equol state
Baseline −1.03 ± 0.46 −1.09 ± 0.733 −1.94 ± 0.30 −1.94 ± 0.44
After 1 week −0.77 ± 0.69 −0.74 ± 0.73 −2.04 ± 0.19 −2.07 ± 0.33 0.802 0.185 0.000 0.702 0.964 0.006 0.960
After 2 weeks −0.92 ± 0.77 −0.82 ± 0.86 −1.83 ± 0.48 −1.62 ± 0.83 0.759 0.097 0.000 0.400 0.864 0.516 0.801
P-value4 (between baseline and after 1 week)
0.343 0.120 0.794 0.890
P-value4 (between baseline and after 2 weeks)
0.578 0.432 0.564 0.383
P-value4 (between 1 and 2 weeks)
0.690 0.921 0.166 0.091
1Urinary equol to daidzein concentration ratios; (equol/daidzein) log. All values are expressed as mean ± SD.
2FOS, fructooligosaccharides.
3Three-way ANOVA (factors of FOS intervention, time, and equol status) was performed to determine the effect of dietary intervention on the urinary equol to daidzein concentration ratios.
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(p = 0.343 and p = 0.120, respectively) or 2 weeks
(p = 0.578 and p = 0.432, respectively) compared with
baseline. Similarly, in equol non-producers, FOS interven-
tion did not affect the urinary equol to daidzein concentra-
tion ratios after 1 week (p = 0.794) or 2 weeks (p = 0.564)
compared with baseline. In equol non-producers, no
significant differences in urinary equol to daidzein concen-
tration ratios in control group between baseline and after 1
week (p = 0.890) or 2 weeks (P = 0.383) were observed.
Moreover, among the equol producers, urinary equol to
daidzein concentration ratios in both the FOS and control
groups was not significantly different between 1 and 2
weeks (p = 0.690 and p = 0.921, respectively). Similarly,
among equol non-producers, urinary equol to daidzein
concentration ratios in both the FOS and control groups
was not significantly different between 1 and 2 weeks
(p = 0.166 and p = 0.091, respectively).
However, significant differences were observed in the
interaction effect of time × equol state after 1 week of
intervention (p = 0.006); however, there were no effects
after 2 weeks of intervention (p = 0.516). One important
reason for this observation could be the intervention
time. Lampe et al. reported that isoflavone excretion did
not differ according to the duration of soy intervention,
whether 4 days or 1 month [26]. On the other hand,
other studies have suggested that long-term exposure to
isoflavone may change the usual plasma concentrations
and urinary excretion of these compounds as result of
altered metabolism [35,36]. After an initial increase,
plasma concentrations of daidzein and genistein
decreased when individuals consumed soy daily over a
2-week period [35]. Lu et al. reported that urinary reco-
very of genistein and daidzein decreased progressively
over 4 weeks of daily soy ingestion but increased for
equol [36]. Thus, such findings have not always been
consistent among studies, and the intervention period
that would elicit an isoflavone response is controversial.
In present study, there were no effects of 2-week FOS
intervention on the capacity of colonic microbiota to pro-
duce equol. Supplementation with FOS and isoflavones
for more than 2 weeks may be required in order to
increase the capacity of colonic microbiota to produce
equol. Another reason for this observation could be the
diet. It is possible that a dietary intake of isoflavone
may affect equol production [16,37]. Japanese diet typic-
ally contains higher amounts of soy products than the
western diets, but the consumption of soy foods during
the study was not controlled. The average daily total
isoflavones (aglycone and conjugates) in this study ranged
from 41.6 – 54.8 mg and isoflavone supplement contains
21 mg aglycone form. If dietary isoflavones may be suffi-
cient isoflavone to saturate equol producer capacity, the
supplement cannot elicit a response. Hence, the increasedequol production in the equol producers after 1 week of
intervention may correlate with isoflavones intake during
this period. If a diet had low isoflavone content in our
study, FOS supplementation may elicit a response by in-
creasing the capacity of colonic microbiota to produce
equol. FOS intervention and time and the interaction ef-
fects of FOS × time, FOS × equol state, and FOS × time
×equol state did not influence the urinary equol to daid-
zein concentration ratios significantly. Hence, our results
suggest that a 2-week intervention with an FOS dosage of
5 g/day does not significantly modulate equol production
both in equol producers and non-producers among post-
menopausal Japanese women. Although we did not assess
the gastrointestinal microbial activity in the present
study, a daily FOS intake of 2.5–10 g for 2–4 weeks
has been reported to have prebiotic effects [25,38].
Additionally, FOS have been reported to increase the
number of faecal bifidobacteria [25,38], affecting the
intestinal microbiotal balance [24]. Ohta et al. reported
that FOS increased equol production from daidzein in
OVX rats [39]. Thus, it is likely that FOS intake produced
similar effects in the present study, although the effects on
equol production were not significant. One possible rea-
son for this observation could be that FOS intake of 5 g/
day may not be sufficient to change and increase the num-
ber of intestinal microbiota required for a significant in-
crease in equol production in humans. It was reported
that the gastrointestinal tolerances of healthy male and fe-
male volunteers to FOS were 0.30 g/kg and 0.40 g/kg, re-
spectively, and a FOS daily intake of up to 30 g was safe
[40,41]. In this study, 5 g FOS was ingested per day.
Therefore, if a much higher level of FOS were used, there
may be effects on the intestinal microbiota of equol pro-
duction. On the other hand, previous studies have
reported that probiotics or prebiotic supplementation with
soy does not affect equol production in American and
Australian populations [26,27,42]. Although certain Lacto-
bacillus and Bifidobacteria species have been suggested to
play a role in the metabolism of daidzein to equol [23,43],
the relevance of dietary-induced changes in gastrointes-
tinal microbiota activity to isoflavone bioavailability is
poorly understood. This suggests that further research ad-
dressing the roles of intestinal microbiota is required to
determine the effects of FOS on equol production.
This is a pilot study, so there are several limitations in
our study. Firstly, with regard to our Japanese subjects,
dietary isoflavones during the study was not controlled.
The Japanese diet contains higher amounts of soy prod-
ucts compared to Western diets. It is possible that a
high dietary intake of isoflavone may have an effect on
the capacity of equol production. Secondly, this study
was carried out with small populations in each group.
Sample size calculation, performed before the start of
the study, showed that with 24 subjects in each group, a
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equol concentration could be shown with a power of
0.80 and two-side type 1 error of 0.05. Thus, it was
seemed that 24 subjects in each group were enough for
the study. However, this study included only 21 equol
producers and 13 equol non-producers. One possible ex-
planation for the non-significant effects of FOS treat-
ment was the insufficient power as a result of the small
sample size. Large scale studies with a similar design on
statistically significant populations are essential to con-
firm our findings. Thirdly, it is a short-term analysis,
and the subjects under review were adults whose gastro-
intestinal microbiotal composition is relatively stable.
Some studies have suggested that long-term exposure to
isoflavones may change the usual plasma concentrations
and urinary excretion of these compounds as result of
altered metabolism [36]. Hence, it is possible that the 2-
week duration of this study was insufficient to alter the
intestinal microbiota for which a longer trial period may
be required. Additionally, the washout period was only 2
weeks, thus carryover effect might exist in our study.
Based on the results derived, we intend to carry out a
large-scale study in which the treatment period and FOS
dose are modified, and dietary isoflavones are controlled.
Conclusion
In conclusion, we have shown that a 2-week intervention
with a daily dose of 5 g FOS does not significantly
modulate the capacity of intestinal microbiota to pro-
duce equol in postmenopausal Japanese women, in ei-
ther the equol producers or the non-producers treated
with isoflavones in this pilot study. However, it may be
possible to stimulate equol production with dietary con-
ditions, especially probiotics such as Lactobacillus and
Bifidobacteria species are added to a diet may be useful,
on long-term intervention. Further large investigations
that explore the roles of specific intestinal microbiota
in equol production will enable the establishment of
dietary conditions that are required to enhance equol
production.
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